Tetra Bio-Pharma Beheer

Beheer criteriumcontroles 3/4

De CEO Tetra Bio-Pharma's is Guy Chamberland, benoemd in Apr2018, heeft een ambtstermijn van 5.17 jaar. bezit rechtstreeks 0.06% van de aandelen van het bedrijf, ter waarde € 5.41K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 5.7 jaar.

Belangrijke informatie

Guy Chamberland

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	5.2yrs
Eigendom CEO	0.06%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	5.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Guy Chamberland's beloning veranderd ten opzichte van Tetra Bio-Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Aug 31 2022	n/a	n/a	-CA$39m
May 31 2022	n/a	n/a	-CA$41m
Feb 28 2022	n/a	n/a	-CA$45m
Nov 30 2021	CA$437k	CA$325k	-CA$52m
Aug 31 2021	n/a	n/a	-CA$29m
May 31 2021	n/a	n/a	-CA$28m
Feb 28 2021	n/a	n/a	-CA$25m
Nov 30 2020	CA$472k	CA$298k	-CA$21m
Aug 31 2020	n/a	n/a	-CA$17m
May 31 2020	n/a	n/a	-CA$15m
Feb 29 2020	n/a	n/a	-CA$14m
Nov 30 2019	CA$295k	CA$214k	-CA$13m
Aug 31 2019	n/a	n/a	-CA$14m
May 31 2019	n/a	n/a	-CA$10m
Feb 28 2019	n/a	n/a	-CA$10m
Nov 30 2018	CA$263k	CA$191k	-CA$8m
Aug 31 2018	n/a	n/a	-CA$5m
May 31 2018	n/a	n/a	-CA$8m
Feb 28 2018	n/a	n/a	-CA$7m
Nov 30 2017	CA$153k	CA$153k	-CA$6m
Aug 31 2017	n/a	n/a	-CA$5m
May 31 2017	n/a	n/a	-CA$4m
Feb 28 2017	n/a	n/a	-CA$2m
Nov 30 2016	CA$131k	CA$60k	-CA$944k

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Guy redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de German markt.

Compensatie versus inkomsten: De vergoeding van Guy is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Guy Chamberland (61 yo)

5.2yrs

Tenure

CA$436,642

Compensatie

Dr. Guy Chamberland, M.Sc., Ph D., Master Herbalist, has been the Chief Executive Officer and Chief Regulatory Officer at Tetra Bio-Pharma Inc. since October 15, 2018 and serves as its Director since June...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Guy Chamberland	Co-Founder	5.2yrs	CA$436.64k	0.060% € 5.4k
Steeve Néron	Chief Commercial Officer	2.8yrs	CA$313.61k	geen gegevens
André Rancourt	Co-Founder	no data	geen gegevens	geen gegevens
Leslie Auld	Chief Financial Officer	1.1yrs	geen gegevens	geen gegevens
Jennifer McCaughey	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Dania Scott	Senior Vice President of Commercial Strategy	2.8yrs	geen gegevens	geen gegevens
Aurelia Pauw	Senior VP of Clinical Programs & Medical Affairs	2.4yrs	geen gegevens	geen gegevens
Richard Giguere	Chief Executive Officer of Tetra Natural Health Inc.	4.7yrs	geen gegevens	geen gegevens
Randy Ringuette	Project Director & Member of Advisory Board	no data	geen gegevens	geen gegevens
Chris MacLean	Chief Operating Officer of Tetra Natural Health	4.1yrs	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van JAM1 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Guy Chamberland	Co-Founder	4yrs	CA$436.64k	0.060% € 5.4k
Randy Ringuette	Project Director & Member of Advisory Board	7.6yrs	geen gegevens	geen gegevens
Catherine Auld	Independent Director	2.1yrs	CA$56.76k	geen gegevens
Steven Edgett	Member of Strategic Advisor	2.9yrs	geen gegevens	geen gegevens
Brent Norton	Independent Chairman	2.8yrs	CA$151.76k	geen gegevens
Adam Greenblatt	Member of Advisory Board	7.6yrs	geen gegevens	geen gegevens
Erin Prosk	Member of Advisory Board	7.6yrs	geen gegevens	geen gegevens
Charles Campbell	Member of Advisory Board	7.6yrs	geen gegevens	geen gegevens
Louis-Philippe de Lorimier	Member of Clinical Advisory Board	5.8yrs	geen gegevens	geen gegevens
Cheryl Cullen	Member of Clinical Advisory Board	5.7yrs	geen gegevens	geen gegevens
Aubrey Webb	Member of Clinical Advisory Board	5.7yrs	geen gegevens	geen gegevens
John Kim	Independent Director	2.1yrs	CA$56.76k	0.096% € 8.6k

5.7yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van JAM1 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.7 jaar).

Tetra Bio-Pharma Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

High number of new and inexperienced directors

Tetra Bio-Pharma Inc. Appoints Leslie Auld as Chief Financial Officer

High number of new and inexperienced directors

Tetra Bio-Pharma Inc., Annual General Meeting, May 28, 2021

Recent updates

Tetra Bio-Pharma Inc. Provides Its Shareholders with Another Regulatory Update on the REDUVO™ New Drug Submission

Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir

Tetra Bio-Pharma Inc. Provides Update on Its REDUVO™ New Drug Submission

Tetra Bio-Pharma Inc. and Prepaire Jointly Apply to BARDA for Funding

Tetra Bio-Pharma Inc. announced that it expects to receive CAD 6 million in funding from Alpha Blue Ocean Advisors Ltd

Tetra Bio-Pharma Inc. Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections

High number of new and inexperienced directors

Tetra Bio-Pharma Inc. Provides Regulatory Update

Tetra Bio-Pharma Inc. Appoints Leslie Auld as Chief Financial Officer

Tetra Bio-Pharma Receives Ema Orphan Drug Designation for A Novel Topical Therapeutic Containing Cbd

Tetra Bio-Pharma Inc. announced that it expects to receive funding from Cannvalate PTY LTD

High number of new and inexperienced directors

Tetra Bio-Pharma Provides Update on Research Collaboration with the University of Montreal Hospital Research Centre for Inhaled CBD

Tetra Bio-Pharma Inc. has completed a Composite Units Offering in the amount of CAD 2.129432 million.

Tetra Bio-Pharma Inc. Announces Positive Initial Clinical Data from its Ongoing Phase 2 Clinical Trials (REBORN©1 and PLENITUDE©) of QIXLEEF™ for Cancer Pain

Tetra Bio-Pharma Accelerates REBORN1© Trial

Significant Discovery Reveals New Antiviral Properties of Tetra Bio- Pharma's Innovative Drug ARDS-003

Independent Chairman of the Board William Cheliak has left the company

Health Canada Accepts New Drug Submission for REDUVO™ as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting

Independent Director has left the company

Tetra Bio-Pharma Announces Clinical Advancements

Tetra Bio-Pharma Inc. has completed a Composite Units Offering in the amount of CAD 10 million.

Tetra Bio-Pharma Inc. Accelerates Plenitude Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain

Tetra Bio-Pharma Announces Start of the Reborn1(C) Clinical Trial

Tetra Bio-Pharma Inc. Re-Activates Veterinary Clinical Study in Companion Animals

Tetra Bio-Pharma Inc., Annual General Meeting, May 28, 2021

Tetra Bio-Pharma Provides Status of its New Drug Submission Application in Canada

Tetra Bio-Pharma Inc. has completed a Composite Units Offering in the amount of CAD 12.54 million.

Tetra Bio-Pharma Inc. (TSX:TBP) entered into a non-binding term sheet to acquire remaining 80% stake in Targeted Pharmaceuticals, LLC for approximately $9.5 million.

New 90-day high: €0.24

Tetra Bio-Pharma Inc. announced that it has received CAD 1.884461 million in funding

Tetra Bio-Pharma Announces FDA Clearance on IND, Allowing U.S. Reborn Clinical Trial to Commence

Tetra Bio-Pharma Inc. announced that it expects to receive CAD 1.894 million in funding

Tetra Bio-Pharma Inc. Completes Investigational New Drug (Ind) -Enabling Toxicology, Clearing the Way for Human Clinical Trials for Its Novel Drug Candidate Ards-003

Tetra Bio-Pharma Inc. Provides Update on Market Potential of ARDS-003

Mondias Natural Products Inc. (TSXV:NHP) completed the acquisition of Lumiera Health Innovation Inc. from Tetra Bio-Pharma Inc. (TSXV:TBP) and certain minority shareholders.

Tetra Bio-Pharma Inc. Unveils Its Commercial Vision on a Robust Chemotherapy Induced Nausea and Vomiting Portfolio

Tetra Bio-Pharma Inc. Enters into A Definitive Agreement with a USA Strategic Partner to Acquire the Canadian Exclusive Rights for Dronabinol Soft Gel Capsules

Tetra Bio-Pharma Inc.(TSXV:TBP) dropped from S&P/TSX Venture Composite Index

Mondias Natural Products Inc. (TSXV:NHP) signed a binding letter of intent to acquire Lumiera Health Innovation Inc. from Tetra Bio-Pharma Inc. (TSXV:TBP) for CAD 1.4 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd